77 results about "Plasmin activity" patented technology

The invention relates to a biotechnology, and particularly discloses a plasmin degradation product D-dimer antibody and application thereof. According to the application, a single B cell antibody preparation technology and a flow cytometry sorting method are applied to the development of a blood coagulation in-vitro diagnosis fibrinolysis system detection antibody for the first time, and a mammalian cell expression system (293F) is adopted to successfully express and obtain three strains of D-dimer monoclonal antibodies (antibody numbers are DD-1, DD-2 and DD-3) with biological activity. Compared with the on-sale Roch D-dimer antibody, the three antibodies have the same affinity with the DD antigen, and can identify and detect the D-dimer in plasma with high specificity and high sensitivity; meanwhile, the probe has no cross reaction with fibrinogen, primary fibrinolytic substances (X, Y and D) and soluble fibrin (SF), and can be used for qualitative or quantitative detection of D-dimer.

The invention provides a dilution buffer solution for chemiluminescence detection of a blood sample. The dilution buffer solution contains 0.05 to 1 weight percent of plasmin and 0.005 to 0.02 weight percent of a de-foaming agent. The dilution buffer solution provided by the invention can reduce the jump value phenomenon in chemiluminescence detection of a blood sample, especially a repeatedly frozen and thawed blood sample, so that a correct and reliable detection result is provided for clinic, and the clinical detection time can be saved.

It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU / mg of defibrotide, preferably from 27 to 32 IU / mg and, more preferably, from 28 to 32 IU / mg.

It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU / mg of defibrotide, preferably from 27 to 32 IU / mg and, more preferably, from 28 to 32 IU / mg.

The invention relates to a biotechnology, and particularly discloses a plasmin degradation product FDP antibody and application thereof. According to the present invention, the single B cell antibody preparation technology and the flow cytometry sorting method are firstly applied to the blood coagulation in vitro diagnosis fibrinolysis system detection antibody development, and the mammalian cell expression system is adopted to successfully express and obtain the three FDP monoclonal antibody strains (the numbers are FDP-1, FDP-2 and FDP-3) with the biological activity; on an ELISA (enzyme-linked immuno sorbent assay) platform, the three FDP recombinant rabbit monoclonal antibodies have specific reaction with primary fibrinolytic substances (X and Y) and secondary fibrinolytic substances (DD); on an immunoturbidimetric platform, the FDP-1 has specific reaction with the primary fibrinolytic substance and the secondary fibrinolytic substance, and the FDP-2 only has specific reaction with the primary fibrinolytic substance on the immunoturbidimetric platform. The three FDP antibodies provided by the invention can make up the vacancy of domestic FDP antibodies on the market, ensure the joint monitoring suitability of D-dimer and FDP, and realize the detection integrity of fibrinolytic system.

The invention discloses a real-time detection method for the activity of fibrinolytic enzyme in whole blood, which comprises the following steps: preparing a fibrinolytic response interference layer film with fibrinolytic enzyme response, and fixing to obtain a microfluidic sample cell; preparing a closed plasmin response and plasmin response interference layer film; analyzing the anti-interference capability of the fibrinolysis response interference layer film on interference protein in whole blood; analyzing the specificity of the fibrinolytic response interference layer film for detecting fibrinolytic enzyme in whole blood; analyzing the sensitivity of the fibrinolytic response interference layer film on the detection of fibrinolytic enzyme in whole blood; diluting the whole blood sample by different multiples with normal saline, introducing the diluted whole blood sample and the diluted whole blood sample with labeled fibrinolytic enzyme into a sample pool formed by the closed fibrinolytic response interference layer film, and detecting the fibrinolytic enzyme activity in the whole blood sample. The method can overcome the interference of colored, complex and viscous whole blood samples, successfully detects the activity of the fibrinolytic enzyme in the whole blood samples, and is stable in detection.

The invention discloses a plasmin lumbrukinase peptide dietary therapy formula suitable for rehabilitation of cardiovascular and cerebrovascular diseases, blood circulation promoting, blood stasis removing, thrombolysis, collateral dredging and microcirculation improving, and relates to the technical field of medicine and food homology dietary therapy. Soybean protein isolate and earthworm protein are used as core thrombolytic active raw materials, isomaltooligosacharide, xylitol, German Jilida collagen peptide, soybean peptide powder, Belgian imported inulin, red yeast rice and natto powder are compounded, microcrystalline cellulose and magnesium stearate are used as auxiliary materials, and probiotics / metabiotics strains such as rhamnolactobacilli JYLR-005 and the like can be selectively added. The raw materials have a synergistic effect through precise matching, plasmin and lumbrukinase peptide in earthworm protein can directly dissolve thrombus fibrin, natto powder and red yeast rice assist in lowering lipid and dissolving thrombus, multiple active peptides and prebiotics regulate intestinal microecology to improve microcirculation of the whole body, probiotics / metabiotics further strengthen the metabolic capacity of the body, no chemical medicine is added in the whole process, and the traditional Chinese medicine composition is free of toxic and side effects and free of toxic and side effects. The safety is high; the dietary therapy composition can achieve postoperative rehabilitation conditioning of cardiovascular and cerebrovascular diseases through daily consumption, effectively promote blood circulation to remove blood stasis, dissolve thrombus and dredge collaterals, improve microcirculation and relieve various discomfort caused by blood vessel clogging, raw materials are easy to obtain, compatibility is scientific, and the dietary therapy composition is suitable for large-scale production and popularization.

The invention discloses a multi-enzyme preparation for industrial cell dissociation as well as a use method and application thereof, and belongs to the technical field of extraction of seed cells for industrial culture of meat. According to the invention, a multi-enzyme preparation composed of a component 1 and a component 2 is adopted; the component 1 comprises neutral protease, hyaluronidase and elastase; and the component 2 comprises matrix metalloproteinase, papain and plasmin. The invention also discloses a preparation method and application of the multienzyme preparation. The reasonable enzyme ratio and the optimized treatment conditions are beneficial to protecting the integrity of cell membranes, maintaining high cell activity and remarkably improving the dissociation efficiency and the cell recovery amount; the complex enzyme preparation is high in adaptability, can be used for various tissue types and dissociation requirements, and is convenient for standardized and large-scale production; in combination with automatic dissociation equipment, the compound enzyme preparation can realize efficient and stable industrial operation, and provides important technical support and wide application prospects for the fields of meat culture industry, tissue engineering, cell therapy and the like.

The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human A2AP. The isolated antibody or antigen-binding fragment according to the present invention i) cross-reacts with rabbit and / or cynomolgus A2AP, ii) does not inhibit human plasmin activity, and iii) increases plasmin mediated clot lysis in the presence of A2AP.

The invention belongs to the technical field of food, and particularly relates to application of nisin in inhibiting plasmin activity and improving quality of milk and / or dairy products. The nisin disclosed by the invention can be used for remarkably inhibiting the activity of plasmin. The nisin disclosed by the invention is a food additive allowed to be used, the INS number is 234, and the nisin is high in safety. Plasmin is a key enzyme causing deterioration of milk and milk quality, and the nisin disclosed by the invention improves the quality of milk and / or dairy products from the source by inhibiting the activity of plasmin.

The invention provides plasmin-targeted complement C3 derived anticoagulant polypeptide and application thereof, and belongs to the technical field of biological medicine. The present invention provides a complement C3-derived anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10), which reduce nerve injury by enhancing the activity of plasmin in degrading fibrin thrombus and promoting the production of matBDNF (matured brain-derived neurotrophic factor), thereby protecting a host from dual threats of inflammatory thrombosis and neurological dysfunction, and also provides a method for preparing the anticoagulant polypeptide (C3-HK10) and a modified peptide (C3-moHK10). And good safety is shown. In conclusion, it is found for the first time that the complement C3 polypeptides C3-HK10 and C3-moHK10 have the characteristic of promoting plasmin activity, have the functions of inhibiting inflammation, thrombus and ischemic cerebral apoplexy injury and relieving nerve injury, and have the potential of becoming anti-inflammatory, thrombus and stroke treatment and neurological function drugs.

To provide a drug that inhibits the interaction between urokinase receptor and urokinase, focusing on various physiological actions caused by the inhibition of plasmin action.SOLUTION: Provided is 1-(2-hydroxyethyl)-2-imidazolidinone (HEI) or derivatives thereof, or salts thereof, as a drug that inhibits the interaction between urokinase receptor and urokinase. 1-(2-hydroxyethyl)-2-imidazolidinone (HEI) or derivatives thereof, or salts thereof, inhibits the action of plasmin through inhibition of the interaction between urokinase receptor and urokinase, and exerts various physiological actions such as inhibition of inflammation, prevention of the degradation of extracellular matrix, and inhibition of cancer invasion.SELECTED DRAWING: Figure 2

The present invention relates to a plasmin inhibitor, a preparation method thereof and an application in the pharmaceutical field. Specifically, the present invention provides a compound represented by formula I, a preparation method thereof and an application in the pharmaceutical field, which relates to the field of medicinal chemistry. In formula I, R1 is H or halogen; R2 and R3 are each independently selected from H, hydroxyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroalicyclic group, substituted or unsubstituted heteroaryl; n = 0, 1 or 2. The compound provided by the present invention has high blood coagulation and hemostasis activities, high blood drug concentration and exposure in vivo, good safety, and has good clinical application prospects.

The present invention relates to an isolated antibody or antigen-binding fragment thereof that binds to human A2AP. The isolated antibody or antigen-binding fragment according to the present invention i) cross-reacts with rabbit and / or cynomolgus A2AP, ii) does not inhibit human plasmin activity, and iii) increases plasmin mediated clot lysis in the presence of A2AP.

The present application relates to a method for promoting the degradation of pathological TDP-43 protein, comprising administering to a subject a therapeutically effective amount of one or more compounds selected from components of the plasminogen activation pathway, compounds that can activate plasminogen directly or indirectly by activating upstream components of the plasminogen activation pathway, compounds that mimic the activity of plasminogen or plasmin, compounds that can upregulate the expression of plasminogen or plasminogen activators, plasminogen analogs, plasmin analogs, tPA or uPA analogs, and antagonists of fibrinolysis inhibitors. The present application also relates to agents that promote the degradation of pathological TDP-43 protein and uses thereof.

This invention discloses a multi-enzyme preparation for industrial cell dissociation, its usage method, and applications, belonging to the field of seed cell extraction technology for industrial meat culture. The invention employs a multi-enzyme preparation composed of component 1 and component 2; component 1 includes neutral protease, hyaluronidase, and elastase; component 2 includes matrix metalloproteinase, papain, and plasmin. The invention also discloses the preparation method and applications of the multi-enzyme preparation. The rational enzyme ratio and optimized treatment conditions of this invention help protect cell membrane integrity, maintain high cell activity, and significantly improve dissociation efficiency and cell recovery. The compound enzyme preparation is highly adaptable, applicable to various tissue types and dissociation requirements, and facilitates standardized and large-scale production. Combined with automated dissociation equipment, the compound enzyme preparation enables efficient and stable industrial operation, providing important technical support and broad application prospects for the cultured meat industry, tissue engineering, and cell therapy.

Disclosed herein are methods and compositions for preserving or conditioning organs prior to transplantation. Compositions of the invention comprise plasmin and / or a functionally active mutant thereof formulated in a pharmaceutically acceptable organ preservation solution. The composition is stable and non-toxic to organs intended for transplantation.

To provide an antigen-binding protein comprising an antigen-binding domain that binds to plasmin. Also provided are compositions comprising the antigen binding proteins, as well as uses thereof and methods of treatment comprising the same.SOLUTION: To provide antigen-binding proteins or antigen-binding fragments thereof that specifically bind to the serine protease domain of plasmin and inhibit or reduce plasmin activity via interaction with the catalytic site of the protein.SELECTED DRAWING: None

This invention discloses the application of the plasmin inhibitor NKI10 in the preparation of drugs for preventing and treating excessive inflammatory responses, belonging to the field of biomedical technology. The amino acid sequence of the plasmin inhibitor NKI10 disclosed in this invention is shown in any one of SEQ ID NO. 1 to 10. The plasmin inhibitor NKI10 can significantly inhibit the production of IL-6, IL-1β, and TNF-α in animal and cellular inflammation models. Since the plasmin inhibitor NKI10 can inhibit excessive inflammatory responses, it can be prepared for use as a drug for preventing and treating excessive inflammatory responses.

The application provides a plasmin alpha2 plasmin inhibitor complex antibody 4C1 and 2D5, the sequence of the heavy chain variable region of the antibody 4C1 is shown as SEQ ID NO:1, and the light chain variable region is shown as SEQ ID NO:2; the sequence of the heavy chain variable region of the antibody 2D5 is shown as SEQ ID NO:9, and the light chain variable region is shown as SEQ ID NO:10. The detection sensitivity of the antibody is high.

The invention discloses a kit and a preparation method and application thereof.The kit is used for detecting the content of plasmin-alpha 2 plasmin inhibitor composites.The kit comprises a first reagent and a second reagent, the first reagent comprises a magnetic particle coated by a plasmin-alpha 2 plasmin inhibitor compound antibody and a magnetic particle buffer solution, and the second reagent comprises a plasmin-alpha 2 plasmin inhibitor compound antibody marked by a marker and an acridine diluent. The kit does not need to be diluted when a sample is tested, and compared with a commercially available Hisenmekang PIC kit, the kit has remarkable correlation; the preparation method can reduce the antibody dosage and simplify the test procedure, and has the advantages of simple operation, low cost and short result obtaining time.

To provide a method and a drug for treating viral pneumonia.SOLUTION: A pharmaceutical composition comprises a therapeutically effective amount of one or more compounds selected from the group consisting of a component of plasminogen activation pathway, a compound capable of activating plasminogen, a compound mimicking the activity of plasminogen or plasmin, a compound capable of upregulating the expression of plasminogen or an activator of plasminogen, an analog of plasminogen, an analog of plasmin, an analog of tPA or uPA, and an antagonist of fibrinolysis inhibitor.SELECTED DRAWING: None

The invention discloses plasmin based on hermetia illucens and application thereof, and belongs to the technical field of biology. The plasmin based on the hermetia illucens is obtained by grinding and centrifuging larvae of the hermetia illucens in a PBS (Phosphate Buffer Solution) and extracting supernate. The invention further provides application of the plasmin based on the hermetia illucens in preparation of thrombolytic drugs. The plasmin is extracted from the hermetia illucens, and the hermetia illucens is short in breeding cycle, high in reproductive capacity, capable of being massively extracted in a short time and low in cost; the extracted plasmin has a remarkable thrombolysis effect and has a very good utilization value; the plasmin can be used for directly dissolving thrombus and degrading fibrinogen.

The invention discloses a tranexamic acid-tyrosinase inhibitor hybrid conjugate as well as a preparation method and application thereof, belongs to the technical field of cosmetics and biological medicines, and particularly relates to a tranexamic acid-tyrosinase inhibitor hybrid conjugate shown in a formula (I) and a skin composition taking the compound as an active component. According to the hybrid conjugate, tranexamic acid and a tyrosinase inhibitor are integrated into a single-structure molecule through an ester bond, so that the transdermal efficiency can be improved and the transdermal dynamic difference limitation of a traditional compound preparation can be broken through by adjusting the hydrophilic-hydrophobic balance of the compound; and plasmin activity can be inhibited through cooperation of tranexamic acid, so that melanin generation signal transmission capability and tyrosinase inhibition capability of tyrosinase inhibitor specificity are reduced, and efficient and mild multi-channel whitening and spot fading are realized. As a whitening active matter, the tranexamic acid-tyrosinase inhibitor hybrid conjugate disclosed by the invention has a great application prospect in the aspects of whitening and freckle removing effects.

The present disclosure provides an ADC comprising a plasmin cleavage site. The ADC according to the present disclosure can have a hydrophobic portion between an antibody and a plasmin cleavage site, and the hydrophobic portion includes no uncharged hydrophilic polymers such as polyethylene glycol (PEG).

The present disclosure provides compositions for hemostasis blood testing, as well as related methods, systems, kits, and sample holders. The compositions include any one or more of (a) a plurality of phospholipids, (b) a plurality of activators, (c) a blood coagulation initiator, and (d) plasmin or a precursor thereof. In some embodiments, the composition further includes one or more of (e) a buffer, (f) a sugar, (g) a protein concentration reference standard, and (h) CaCl2.

The present invention relates to a new use of recombinant human ocella plasmin in the preparation of a medicament for the treatment and / or prevention of choroidal vascular diseases.

The present invention provides a new plasminogen activator from velvet antler mushroom and a preparation method and application thereof, and belongs to the field of bioengineering technology. The new plasminogen activator from velvet antler mushroom provided by the present invention is composed of a single subunit, and the molecular weight of the new plasminogen activator is 30.9 kDa; the twelve amino acid sequences at the N-terminus of the new plasminogen activator are shown in SEQ ID NO.1, and after comparison with the NCBI database, it is a new plasminogen activator. The new plasminogen activator from velvet antler mushroom provided by the present invention can sequentially degrade the α, β and γ chains of human fibrinogen, and the degradation time is short; at the same time, the new plasminogen activator can also dissolve blood clots, and has a good thrombolytic effect. In addition, the plasminogen activator from velvet antler mushroom provided by the present invention has high safety, is easy to be absorbed by the human body, has low production cost, and has a prospect for development and application.

The present invention belongs to the field of biomedicine technology, and specifically relates to a novel recombinant protein Plasminogen-CTM and its application. The present invention first provides a novel recombinant protein Plasminogen based on natural Plasminogen protein, and after the amino acid sites 742-810 of the natural Plasminogen protein are mutated in a combined manner, multiple recombinant protein mutants are obtained. The novel recombinant protein Plasminogen provided by the present invention has enzyme activity without activation by an activator, and can therefore be an effective means to replace natural plasmin directly isolated from plasma.

The invention belongs to the technical field of biological medicine, and particularly relates to a novel recombinant protein Plasminogen-CTM and application thereof. The invention firstly provides a novel recombinant protein Plasminogen, and the novel recombinant protein Plasminogen is based on a natural Plasminogen protein, and a plurality of recombinant protein mutants are obtained after multi-site mutation is carried out on the 742 to 810 amino acid sites of the natural Plasminogen protein in a combined manner. The novel recombinant protein Plasminogen provided by the invention has enzyme activity without being activated by an activator, so that the novel recombinant protein Plasminogen can become an effective means for replacing natural plasmin directly separated from plasma.